GW Pharma Epilepsy Research in Australia Receives $6mm Government Funding Support
With the completion of two Phase 3 clinical trials that showed its Epidiolex to be safe and effective, global interest in GW Pharma’s (NASDAQ: GWPH) pharmaceutical-grade cannabidiol (CBD) extracted from cannabis continues...